Quanterix Opens Call For Proposals For Second Annual Accelerator Grant Program Focused On Oncology And Liquid Tumor Biopsy Technology
Lexington, Mass. – April 18, 2016 – Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing. Since its launch in 2014, the Lab has grown from one to four instruments, expanding its capabilities to run up to 2,400 different samples a day.
Quanterix’ revolutionary next-generation ultrasensitive digital immunoassay platform offers unprecedented opportunities to drive profound research and innovation in life sciences and drug research, showcasing tremendous value across several therapeutic areas. Furthering the Company’s mission to stimulate rapid growth and innovation in healthcare, Quanterix invites organizations, academics and independent researchers to submit oncology-focused research proposals for a chance to secure access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, and this state-of-the-art Lab. While all projects in oncology will be considered, those that aid in the advancement of liquid tumor biopsies will receive special consideration.
“There is mounting evidence demonstrating Simoa’s potential to positively impact the growing fields of liquid tumor biopsies and early disease detection before symptoms are present. With this in mind, and as we look to expand our research in oncology, we’re excited to see what this next round of proposals will bring,” said Kevin Hrusovsky, Executive Chairman and CEO, Quanterix.
Dr. Brad Quon, the recipient of Quanterix’ first Accelerator Lab grant, is a Clinician-Scientist from the University of British Columbia St. Paul’s Hospital Centre for Heart Lung Innovation (Vancouver, Canada). His innovative biomarker development program is focused on discovering and validating blood-based biomarkers to predict impending pulmonary exacerbations in cystic fibrosis (CF). These findings would allow doctors to use these new blood tests to target – the right treatment to the right patient at the right time – to prevent pulmonary exacerbations.
“Using Quanterix’ Simoa HD-1 analyzer has strengthened my research program by enabling the detection and quantification of protein biomarkers previously considered difficult or impossible to measure,” said Dr. Quon. “In prior work, I’ve demonstrated that a six-protein biomarker identified with multiple reaction monitoring mass spectrometry (MRM-MS) can predict impending pulmonary exacerbations with reasonable confidence, but to enhance the robustness of this prognostic biomarker to benefit patients further, we need the detection capabilities that only Simoa can provide. Utilizing the Simoa Cytokine 3-Plex panel, we’ll have the ability to test hundreds of clinical samples to better evaluate the potential of these biomarkers and identify patients with pulmonary exacerbations.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, visit: www.quanterix.com and follow @QuanterixSimoa on Twitter. Investors can access a webcast of Kevin Hrusovsky’s recent JPMorgan presentation at: http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation.
Share this page